HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
2019 · Gastroenterology · 400 citations
https://doi.org/10.1053/j.gastro.2019.09.041
P
Peter M. Irving
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
701
Papers
19.3K
Citations
74
h-index
207
i10-index
Peter M. Irving is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 74, co-authored 596 publications.
ORCID: 0000-0003-0972-8148Papers by this author
worksHLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
2019 · Gastroenterology · 400 citations
https://doi.org/10.1053/j.gastro.2019.09.041
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
2022 · The Lancet · 277 citations
https://doi.org/10.1016/s0140-6736(22)00688-2
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
2022 · The Lancet · 277 citations
https://doi.org/10.1016/s0140-6736(22)00688-2
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
2024 · The Lancet. Gastroenterology & hepatology · 239 citations
https://doi.org/10.1016/s2468-1253(24)00034-7
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
2024 · The Lancet. Gastroenterology & hepatology · 239 citations
https://doi.org/10.1016/s2468-1253(24)00034-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat